Risankizumab versus adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal. Al-Janabi A, Warren RB. Br J Dermatol 2020 Jan 3. doi: 10.1111/bjd.18856.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Al-Janabi A, Warren RB. Risankizumab versus adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal. Br J Dermatol 2020 Jan 3. doi: 10.1111/bjd.18856.
PMID: 31899817